These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22615288)

  • 1. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.
    Wroblewski HA; Kovacs RJ; Kingery JR; Overholser BR; Tisdale JE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4495-9. PubMed ID: 22615288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmias associated with fluoroquinolone therapy.
    Falagas ME; Rafailidis PI; Rosmarakis ES
    Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
    Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
    Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole.
    Yamamoto K; Tamura T; Imai R; Yamamoto M
    Toxicol Sci; 2001 Mar; 60(1):165-76. PubMed ID: 11222883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine.
    El-Eraky H; Thomas SH
    Br J Clin Pharmacol; 2003 Aug; 56(2):198-204. PubMed ID: 12895193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT; Chow MS; Kluger J
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure.
    Stanek EJ; Simko RJ; DeNofrio D; Pavri BB
    Pharmacotherapy; 1997; 17(3):622-5. PubMed ID: 9165569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torsades de pointes and ventricular fibrillation in a canine model of quinidine-induced QT prolongation.
    Inoue H; Sugimoto T
    Ann N Y Acad Sci; 1992 Jan; 644():93-102. PubMed ID: 1562122
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
    Chézalviel-Guilbert F; Deplanne V; Davy JM; Poirier JM; Xia YZ; Cheymol G; Weissenburger J
    J Cardiovasc Electrophysiol; 1998 May; 9(5):498-507. PubMed ID: 9607458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
    Farkas A; Leprán I; Papp JG
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QTc prolongation, torsades de pointes, and psychotropic medications.
    Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
    Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Late" proarrhythmia due to quinidine.
    Oberg KC; O'Toole MF; Gallastegui JL; Bauman JL
    Am J Cardiol; 1994 Jul; 74(2):192-4. PubMed ID: 8023791
    [No Abstract]   [Full Text] [Related]  

  • 18. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM
    Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.